Edward A Sausville

6562859, May 13, 2003

Aug 4, 2000

09/555733

O. M. Zack Howard - Frederick MD
Joost J. Oppenheim - Bethesda MD
William J. Murphy - Frederick MD
Edward A. Sausville - Silver Spring MD

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K 3140

514422, 514518

A method of using a ureido derivative of a poly-4-amino-2-carboxy-1-methyl pyrrole or a pharmaceutically acceptable salt thereof to inhibit inflammation, particularly non-TNF- dependent inflammation, in a mammal.

6610684, Aug 26, 2003

Dec 14, 2000

09/739534

Daniel W. Zaharevitz - Camp Springs MD
Rick P. Gussio - Frederick MD
Ravi K. Jalluri - San Diego CA
Edward A. Sausville - Silver Spring MD
Conrad Kunick - Hamburg, DE
Laurent Meijer - Roscoff, FR

The United States of America as represented by the Department of Health and Human Services - Washington DC
Centre National de la Recherche Scientifique

C07D48704

51421206, 540521

A new class of cyclin dependent kinase inhibitors that also have antiproliferative activity in human tumor cell line assays are described. Most of these compounds satisfy the formula wherein A is oxygen or sulfur coupled to the right by a single or double bond; R is selected from the group consisting of hydrogen, aryl, lower aliphatic substituents, particularly alkyl and lower alkyl ester; R -R are independently selected from the group consisting of alkoxy, amino, acyl, aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, aliphatic alcohols, particularly alkyl alcohols, aliphatic nitriles, particularly alkyl nitriles, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, imino, and , , unsaturated ketones; R -R are independently selected from the group consisting of aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, particularly lower aliphatic substituents, alipahatic alcohols, particularly alkyl alcohols, alkoxy, acyl, cyano, nitro, epoxy, haloalkyl groups, halogen, hydrogen and hydroxyl; R is selected from the group consisting of aliphatic groups, particularly lower alkyl groups, aliphatic alcohols, particularly alkyl alcohols, carboxylic acids and hydrogen. Compositions comprising effective amounts of such compounds also are described. These compounds and compositions can be used in a method for inhibiting the proliferation of living cells in a subject comprising administering an effective amount of the compound(s), or composition(s) comprising the compound(s), to a subject to inhibit the proliferation of living cells, such as neoplastic cells.

6890917, May 10, 2005

Mar 28, 2002

10/432581

Kenneth M. Snader - Germantown MD, US
B. Rao Vishnuvajjala - Rockville MD, US
Melinda G. Hollingshead - Middletown MD, US
Edward A. Sausville - Silver Spring MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

C07D225/06
A61K031/395

514183, 540461

A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.

6943191, Sep 13, 2005

Feb 24, 1999

09/623000

Venkatachala L. Narayanan - Gaithersburg MD, US
Edward A. Sausville - Silver Spring MD, US
Gurmeet Kaur - Germantown MD, US
Ravi K. Varma - Rockville MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K031/24
A61K031/195
C07C229/00

514535, 514563, 560 46

Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the disclosure, without limitation, satisfy either Formula 1 or Formula 2. The present disclosure also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs and potentially comprising other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the disclosure can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.

8580519, Nov 12, 2013

Nov 26, 2007

12/515770

Angelika M. Burger - Baltimore MD, US
Edward A. Sausville - Silver Spring MD, US

University of Maryland, Baltimore - Baltimore MD

G01N 33/53

435 71

The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.

20100260753, Oct 14, 2010

Oct 22, 2008

12/739407

Angelika Burger - Detroit MI, US
Edward Sausville - Silver Spring MD, US
Phillip Shelton - Baltimore MD, US

A61K 31/352
A61K 31/566
A61K 31/4196
A61K 31/506
A61K 39/395
A61K 31/517
A61P 35/00

4241331, 514456, 514171, 514383, 514274, 51426624

Disclosed are methods of treating breast cancer by administering to a mammal aminoflavone, and optionally one or more additional anti-cancer agents. According to example embodiments, the methods include methods of treating cancers resistant to endocrine therapy.

20130177904, Jul 11, 2013

Feb 23, 2011

13/580563

Averell L. Gnatt - Pikesville MD, US
Edward A. Sausville - Silver Spring MD, US
Phillip Shelton - Baltimore MD, US
Hui Yang - Catonsville MD, US

UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD

C12Q 1/68
G01N 33/68

435 611, 435 71

The present invention is directed to methods for determining whether a selected cancer is susceptible to an activity of an arylhydrocarbon receptor agonist, such as aminoflavone, via screening the cancer for expression of isoform 3 of aryl hydrocarbon nuclear translocator.

56021844, Feb 11, 1997

Mar 3, 1993

8/025471

Charles E. Myers - Rockville MD
Jane Trepel - Bethesda MD
Edward Sausville - Silver Spring MD
Dvorit Samid - Rockville MD
Alexandra Miller - Hyattsville MD
Gregory Curt - Rockville MD

The United States of America as represented by Department of Health and
Human Services - Washington DC

H61K 31045

514739

The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.